# A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

> **NCT03516591** · PHASE1 · COMPLETED · sponsor: **Amphivena Therapeutics, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** AMV564 14-Day CIV

## Key facts

- **NCT ID:** NCT03516591
- **Lead sponsor:** Amphivena Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-22
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516591, "A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03516591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*